SCHEMBL5578149

SCHEMBL5578149

NCc1nc(-c2n[nH]cc2NC(=O)c2c(F)cccc2F)[nH]c1-c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.39
CDK1 P06493 2/20 0.39
CCNA2 P20248 2/20 0.39
CCNB1 P14635 1/20 0.39
CCNA1 P78396 1/20 0.39
MAPT P10636 2/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
ALOX5 P09917 3/20 0.36
MAPK14 Q16539 2/20 0.35
CSNK1D P48730 1/20 0.35
CSNK1E P49674 1/20 0.35
DYRK3 O43781 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
ABL1 P00519 1/20 0.35
EGFR P00533 1/20 0.35
NTRK1 P04629 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578190 0.87 CDK1 (0.36) CDK2CDK1CCNA2CCNB1CCNA1
SCHEMBL14511697 0.85 MAPT (0.38) CDK2CDK1CCNA2CCNB1CCNA1
SCHEMBL14511698 0.84 WNT1 (0.37) CDK2CDK1CCNA2CCNB1CCNA1
SCHEMBL5578138 0.84 BCL3 (0.45) CDK2CDK1CCNB1ALOX5AURKB
SCHEMBL5578187 0.82 CDK1 (0.37) CDK2CDK1CCNA2CCNB1CCNA1
SCHEMBL5578102 0.81 MAPT (0.40) CDK2CDK1MAPTMEN1KMT2A
SCHEMBL5578095 0.81 MAPT (0.40) CDK2CDK1MAPTMEN1KMT2A
SCHEMBL5578169 0.80 KMT2A (0.46) CDK2CDK1MAPTMEN1KMT2A
SCHEMBL14511699 0.80 BCL3 (0.49) CDK2CDK1CCNA2CCNB1KMT2A
SCHEMBL5578475 0.79 PARP1 (0.42) CDK2MAP4K4ABL1EGFRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed
EP-1648449-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS Astex Therapeutics Limited (GB) 2006-04-26 EP disclosed
WO-2005002576-A2 IMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105900-A1 Pharmaceutical compounds AURKA, AURKC, CDK1 CDK2 5/4885CDK1 3/4885CCNA2 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.